Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP309474.RAQmYkU698y7KbGcPS0vfHRNoPs5mqtsZ0F7E2G4R3blM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP309474.RAQmYkU698y7KbGcPS0vfHRNoPs5mqtsZ0F7E2G4R3blM130_assertion type Assertion NP309474.RAQmYkU698y7KbGcPS0vfHRNoPs5mqtsZ0F7E2G4R3blM130_head.
- NP309474.RAQmYkU698y7KbGcPS0vfHRNoPs5mqtsZ0F7E2G4R3blM130_assertion description "[In view of these findings, the anti-CD20 chimeric monoclonal antibody, rituximab (Rituxan; Genentech, Inc, South San Francisco, CA and IDEC Pharmaceutical Corporation, San Diego, CA), has been evaluated in the treatment of Waldenstrom's macroglobulinemia and multiple myeloma, as well as in nonmalignant plasma cell disorders including IgM polyneuropathies, immune thrombocytopenias, and autoimmune hemolytic anemias, with reported activity in these entities.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP309474.RAQmYkU698y7KbGcPS0vfHRNoPs5mqtsZ0F7E2G4R3blM130_provenance.
- NP309474.RAQmYkU698y7KbGcPS0vfHRNoPs5mqtsZ0F7E2G4R3blM130_assertion evidence source_evidence_literature NP309474.RAQmYkU698y7KbGcPS0vfHRNoPs5mqtsZ0F7E2G4R3blM130_provenance.
- NP309474.RAQmYkU698y7KbGcPS0vfHRNoPs5mqtsZ0F7E2G4R3blM130_assertion SIO_000772 11226004 NP309474.RAQmYkU698y7KbGcPS0vfHRNoPs5mqtsZ0F7E2G4R3blM130_provenance.
- NP309474.RAQmYkU698y7KbGcPS0vfHRNoPs5mqtsZ0F7E2G4R3blM130_assertion wasDerivedFrom befree-2016 NP309474.RAQmYkU698y7KbGcPS0vfHRNoPs5mqtsZ0F7E2G4R3blM130_provenance.
- NP309474.RAQmYkU698y7KbGcPS0vfHRNoPs5mqtsZ0F7E2G4R3blM130_assertion wasGeneratedBy ECO_0000203 NP309474.RAQmYkU698y7KbGcPS0vfHRNoPs5mqtsZ0F7E2G4R3blM130_provenance.